US Patent

US9376680 — Serpinc1 iRNA compositions and methods of use thereof

Method of Use · Assigned to Alnylam Pharmaceuticals Inc · Expires 2033-03-15 · 7y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects iRNA compositions targeting the Serpinc1 gene and methods of using them to inhibit Serpinc1 expression and treat bleeding disorders.

USPTO Abstract

The invention relates to iRNA, e.g., double-stranded ribonucleic acid (dsRNA), compositions targeting the Serpinc1 gene, and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of Serpinc1 and methods of treating subjects having a bleeding disorder, such as a hemophilia.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4165`	—
`U-4165`	—

Patent Metadata

Patent number: US9376680
Jurisdiction: US
Classification: Method of Use
Expires: 2033-03-15
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Alnylam Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.